Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice

被引：13

作者：

Han, Jinsheng ^{[1
]}

Gao, Fei ^{[1
,2
]}

Geng, Songsong ^{[4
]}

Ye, Xueshuai ^{[1
]}

Wang, Tie ^{[3
,4
]}

Du, Pingping ^{[4
]}

Cai, Ziqi ^{[4
]}

Fu, Zexian ^{[5
]}

Zhao, Zhilong ^{[6
]}

Shi, Long ^{[7
]}

Li, Qingxia ^{[2
]}

Cai, Jianhui ^{[1
,2
]}

机构：

[1] Hebei Med Univ, Dept Surg, Shijiazhuang, Hebei, Peoples R China

[2] Hebei Gen Hosp, Dept Surg & Oncol, Shijiazhuang, Hebei, Peoples R China

[3] Hebei HOFOY Biotech Co Ltd, Hebei Engn Technol Res Ctr Cell Therapy, Shijiazhuang, Hebei, Peoples R China

[4] Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Surg, Cangzhou, Hebei, Peoples R China

[5] Hebei Engn Univ, Dept Surg, Affiliated Hosp, Handan, Hebei, Peoples R China

[6] Jinzhou Med Univ, Dept Surg, Affiliated Hosp 3, Jinzhou, Liaoning, Peoples R China

[7] Hebei Med Univ, Dept Oncol, Hosp 2, Shijiazhuang, Hebei, Peoples R China

来源：

MOLECULAR CANCER THERAPEUTICS | 2020年 / 19卷 / 01期

关键词：

CHIMERIC ANTIGEN RECEPTOR; EXPRESSION; VECTOR; TRANSPOSON; THERAPY;

D O I：

10.1158/1535-7163.MCT-19-0204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Viral-based chimeric antigen receptor-engineered T (CAR T)-cell manufacturing has potential safety risks and relatively high costs. The nonviral minicircle DNA (mcDNA) is safer for patients, cheaper to produce, and may be a more suitable technique to generate CAR T cells. In this study, we produced mcDNA-based CAR T cells specifically targeting prostate stem cell antigen (PSCA; mcDNA-PSCA-CAR T cells). Our results showed that mcDNA-PSCA-CAR T cells persisted in mouse peripheral blood as long as 28 days and demonstrated more CAR T-cell infiltration, higher cytokine secretion levels, and better antitumor effects. Together, our results suggest that mcDNA-CAR can be a safe and cost-effective platform to produce CAR T cells.

引用

页码：178 / 186

页数：9

共 50 条

[31] CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Porcellini, Simona
Asperti, Claudia
Corna, Stefano
Cicoria, Eleonora
Valtolina, Veronica
Stornaiuolo, Anna
Valentinis, Barbara
Bordignon, Claudio
Traversari, Catia
FRONTIERS IN IMMUNOLOGY, 2020, 11
[32] Genetically engineered CAR T cells to hack prostate cancer TME
Maria Chiara Masone
Nature Reviews Urology, 2022, 19 : 255 - 255
[33] Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
Zohreh Sadat Badieyan
Sayed Shahabuddin Hoseini
Archivum Immunologiae et Therapiae Experimentalis, 2018, 66 : 283 - 288
[34] Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
Badieyan, Zohreh Sadat
Hoseini, Sayed Shahabuddin
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2018, 66 (04) : 283 - 288
[35] Production of Human CRISPR-Engineered CAR-T Cells
Agarwal, Sangya
Wellhausen, Nils
Levine, Bruce L.
June, Carl H.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (169):
[36] Genetically engineered CAR T cells to hack prostate cancer TME
Masone, Maria Chiara
NATURE REVIEWS UROLOGY, 2022, 19 (05) : 255 - 255
[37] Enhancing Tumor Directed T Cells with a Costimulatory CAR
Cardenas, Mara G.
Daum, Rachel
Rooney, Cliona M.
Arber, Caroline
Omer, Bilal
MOLECULAR THERAPY, 2020, 28 (04) : 211 - 211
[38] Dual-specific T Cells: Combining Car-engineered T Cells With Oncolytic Virotherapy
VanSeggelen, Heather
Hammill, Joanne A.
Bassett, Jennifer D.
Evelegh, Carole
Denisova, Galina F.
Rabinovich, Brian
Bramson, Jonathan L.
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 728 - 728
[39] ACTIVE MODULATION OF THE TUMOR MICROENVIRONMENT BY ENGINEERED T CELLS
Ceccarello, E.
Tabaglio, T.
Boon, D. W. K.
Teo, W. K. L.
Tan, D. Z. M.
Aw, J. J. Y.
Koh, S. S. F.
Pavesi, A.
Guccione, E.
Bertoletti, A.
HUMAN GENE THERAPY, 2018, 29 (11) : A10 - A10
[40] TCR engineered T cells for solid tumor immunotherapy
Zhang, Yikai
Liu, Zhipeng
Wei, Wei
Li, Yangqiu
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)

← 1 2 3 4 5 →